This dataset presents morphological features, elemental composition and functional groups of different pre- and post-gamma (γ)-irradiated chitosan (10kGy & 20kGy) prepared from shrimp waste. The γ-irradiated chitosan was characterized using Fourier transfer infrared (FTIR) spectroscopy and X-ray diffraction (XRD) analyses. Thermogravimetry/differential thermal analysis (TG/DTA) were performed using Perkin Elmer Pyris Diamond DSC with a heating rate of 10 °C/minute and dynamic synthetic atmospheric air set at flow rate of 100 ml/minute. We observed γ-irradiated chitosan to have shorter polymer size, small pores and compacted structure with active alkyl and hydroxyl groups when compared to non-irradiated chitosan. Our data provides baseline understanding for structure of shrimp chitosan after 60Co exposure which means, the biopolymer becomes more stable and is considered suitable for vast food industry applications.
Natural product extraction is ingenuity that permits the mass manufacturing of specific products in a cost-effective manner. With the aim of obtaining an alternative chitosan supply, the carapace of dead horseshoe crabs seemed feasible. This sparked an investigation of the structural changes and antioxidant capacity of horseshoe crab chitosan (HCH) by γ-irradiation using 60Co source. Chitosan was extracted from the horseshoe crab (Tachypleus gigas; Müller) carapace using heterogeneous chemical N-deacetylation of chitin, followed by the irradiation of HCH using 60Co at a dose-dependent rate of 10 kGy/hour. The average molecular weight was determined by the viscosimetric method. Regarding the chemical properties, the crystal-like structures obtained from γ-irradiated chitosan powders were determined using Fourier transfer infrared (FTIR) spectroscopy and X-ray diffraction (XRD) analyses. The change in chitosan structure was evident with dose-dependent rates between 10 and 20 kGy/hour. The antioxidant properties of horseshoe crab-derived chitosan were evaluated in vitro. The 20 kGy γ-irradiation applied to chitosan changed the structure and reduced the molecular weight, providing sufficient degradation for an increase in antioxidant activity. Our findings indicate that horseshoe crab chitosan can be employed for both scald-wound healing and long-term food preservation due to its buffer-like and radical ion scavenging ability.
COVID-19 is a disease that puts most of the world on lockdown and the search for therapeutic drugs is still ongoing. Therefore, this study used in silico screening to identify natural bioactive compounds from fruits, herbaceous plants, and marine invertebrates that are able to inhibit protease activity in SARS-CoV-2 (PDB: 6LU7). We have used extensive screening strategies such as drug likeliness, antiviral activity value prediction, molecular docking, ADME, molecular dynamics (MD) simulation, and MM/GBSA. A total of 17 compounds were shortlisted using Lipinski's rule in which 5 compounds showed significant predicted antiviral activity values. Among these 5, only 2 compounds, Macrolactin A and Stachyflin, showed good binding energy of -9.22 and -8.00 kcal/mol, respectively, within the binding pocket of the Mpro catalytic residues (HIS 41 and CYS 145). These two compounds were further analyzed to determine their ADME properties. The ADME evaluation of these 2 compounds suggested that they could be effective in developing therapeutic drugs to be used in clinical trials. MD simulations showed that protein-ligand complexes of Macrolactin A and Stachyflin with the target receptor (6LU7) were stable for 100 nanoseconds. The MM/GBSA calculations of Mpro-Macrolactin A complex indicated higher binding free energy (-42.58 ± 6.35 kcal/mol). Dynamic cross-correlation matrix (DCCM) and principal component analysis (PCA) on the residual movement in the MD trajectories further confirmed the stability of Macrolactin A bound state with 6LU7. In conclusion, this study showed that marine natural compound Macrolactin A could be an effective therapeutic inhibitor against SARS-CoV-2 protease (6LU7). Additional in vitro and in vivo validations are strongly needed to determine the efficacy and therapeutic dose of Macrolactin A in biological systems.